{"id":351205,"date":"2025-08-25T20:35:15","date_gmt":"2025-08-25T20:35:15","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-syndax-pharmaceuticals\/"},"modified":"2025-08-25T20:35:15","modified_gmt":"2025-08-25T20:35:15","slug":"how-to-buy-syndax-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/","title":{"rendered":"How to buy Syndax Pharmaceuticals, Inc. (SNDX) shares &#8211; Investment in Syndax Pharmaceuticals, Inc. (SNDX) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334099,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-351205","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy Syndax Pharmaceuticals, Inc. (SNDX) Shares - Investment in Syndax Pharmaceuticals, Inc. (SNDX) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy Syndax Pharmaceuticals, Inc. (SNDX) Shares - Investment in Syndax Pharmaceuticals, Inc. (SNDX) Stock"},"description":"Learn how to buy Syndax Pharmaceuticals, Inc. (SNDX) shares and discover investment opportunities in this promising biotech stock with 986% revenue growth and FDA Priority Review status.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to buy Syndax Pharmaceuticals, Inc. (SNDX) shares and discover investment opportunities in this promising biotech stock with 986% revenue growth and FDA Priority Review status."},"intro":"Imagine owning a piece of a company that just reported 986% revenue growth and received FDA Priority Review for its breakthrough cancer treatment. Syndax Pharmaceuticals represents the explosive potential of biotech investing\u2014where scientific breakthroughs can translate into extraordinary returns. This isn't just about buying stock; it's about investing in medical innovation that could change lives and portfolios.","intro_source":{"label":"Intro","type":"text","formatted_value":"Imagine owning a piece of a company that just reported 986% revenue growth and received FDA Priority Review for its breakthrough cancer treatment. Syndax Pharmaceuticals represents the explosive potential of biotech investing\u2014where scientific breakthroughs can translate into extraordinary returns. This isn't just about buying stock; it's about investing in medical innovation that could change lives and portfolios."},"body_html":"<h2>\ud83d\udcc8 Current Market Position and Immediate Opportunities<\/h2> <p>As of August 25, 2025, Syndax Pharmaceuticals (SNDX) trades at <strong>$15.74<\/strong> per share. But here's what makes this moment particularly exciting: mark your calendar for <strong>November 4, 2025<\/strong>\u2014the company's next earnings release date.<\/p> <h3>Why November 4th Matters:<\/h3> <p>Based on recent history, Syndax's earnings reports have been absolute game-changers. Their Q2 2025 report on August 4th caused a massive 15.8% single-day surge after they smashed expectations with 986% year-over-year revenue growth. The pattern is clear: when Syndax reports, the market listens\u2014and reacts dramatically.<\/p> <h3>Recent Earnings Impact Analysis:<\/h3> <ul> <li>August 4, 2025: +15.8% surge post-earnings (986% revenue growth beat)<\/li> <li>May 2025: Positive clinical data at EHA Congress sparked institutional buying<\/li> <li>February 2025: Steady accumulation by smart money investors<\/li> <\/ul> <p>The trend shows that positive clinical and financial news creates immediate, substantial price movements. For traders, this means positioning before these catalysts can be incredibly rewarding.<\/p> [cta_green text=\"Start trading\"]<h2>\ud83d\udcca Six-Month Price Journey: From Struggle to Breakout<\/h2> <p>Syndax's stock has been on an emotional rollercoaster that perfectly illustrates biotech volatility:<\/p> <ul> <li><strong>January-March 2025:<\/strong> Consolidation around $9-11 range<\/li> <li><strong>April-June 2025:<\/strong> Gradual climb to $13-14 on institutional accumulation<\/li> <li><strong>July 2025:<\/strong> Brief pullback to $9.87 (perfect buying opportunity in hindsight)<\/li> <li><strong>August 2025:<\/strong> Explosive breakout to $15.74+ on stellar earnings<\/li> <\/ul> <p>The 6-month chart shows a classic \"accumulation-breakout\" pattern where smart money built positions before the big news hit. From the July lows around $9.87 to current levels above $15, that's a <strong>59% gain<\/strong> in just weeks\u2014the kind of move that defines biotech investing.<\/p> <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <ul> <li><strong>2025 Year-End:<\/strong> $33-38 range (110-140% upside from current levels)<br> <em>Rationale: FDA decision on October 25th + continued revenue acceleration<\/em><\/li> <li><strong>2026 Forecast:<\/strong> $45-55 range<br> <em>Potential catalysts: Additional label expansions, international approvals<\/em><\/li> <li><strong>2028 Projection:<\/strong> $60-75 range<br> <em>Assuming successful commercialization and pipeline development<\/em><\/li> <li><strong>2030 Vision:<\/strong> $80-100+ potential<br> <em>Blockbuster drug status if current trajectory continues<\/em><\/li> <\/ul> <p><strong>Verdict: STRONG BUY<\/strong> - The combination of exploding revenue, FDA catalysts, and reasonable valuation creates a rare opportunity.<\/p> <h2>\u26a0\ufe0f Understanding the Risks: Biotech Reality Check<\/h2> <p>While the upside potential is enormous, Syndax carries significant risks that every investor must understand:<\/p> <ul> <li><strong>Regulatory Risk:<\/strong> The October 25th FDA decision could go either way<\/li> <li><strong>Clinical Trial Risk:<\/strong> Future studies might not replicate early success<\/li> <li><strong>Cash Burn:<\/strong> Despite growth, the company still burns substantial cash<\/li> <li><strong>Volatility:<\/strong> 52-week range of $8.58-$22.50 shows extreme price swings<\/li> <li><strong>Pipeline Concentration:<\/strong> Heavy reliance on Revuforj success<\/li> <\/ul> <p>However, the current $517.9 million cash position provides ample runway, reducing immediate dilution risk.<\/p> <h2>\ud83d\ude80 Positive Signals Overwhelming Risks<\/h2> <p>The bullish case for Syndax is compelling:<\/p> <ul> <li><strong>986% Revenue Growth:<\/strong> Not a typo\u2014actual Q2 2025 performance<\/li> <li><strong>FDA Priority Review:<\/strong> October 25th decision date for expanded approval<\/li> <li><strong>Institutional Support:<\/strong> Major funds increasing positions significantly<\/li> <li><strong>First-Mover Advantage:<\/strong> Only menin inhibitor with proven efficacy<\/li> <li><strong>Market Expansion:<\/strong> Potential addressable market increase from 5% to 30% of AML patients<\/li> <\/ul> <h2>\ud83c\udfaf What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Start Small:<\/strong> Allocate only what you can afford to lose completely\u2014biotech is high-risk<\/li> <li><strong>Dollar-Cost Average:<\/strong> Buy in increments rather than all at once<\/li> <li><strong>Set Alert for November 4th:<\/strong> Earnings could be another massive catalyst<\/li> <li><strong>Consider October Puts:<\/strong> Hedge against FDA decision risk<\/li> <\/ol> <p>And my favorite trader wisdom: \"Buying biotech stocks is like dating\u2014sometimes you get the breakthrough treatment, sometimes you get the side effects. Always read the clinical data before committing!\"<\/p> <h2>\u2705 How to Buy Syndax Pharmaceuticals, Inc. (SNDX) Shares - Step by Step<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose a Trading Platform<\/td><td>Ensure it offers NASDAQ listings and biotech stocks<\/td><\/tr> <tr><td>2<\/td><td>Complete Account Funding<\/td><td>Start with a comfortable amount\u2014even $100 can begin your journey<\/td><\/tr> <tr><td>3<\/td><td>Search \"SNDX\"<\/td><td>Use the exact ticker symbol for accurate results<\/td><\/tr> <tr><td>4<\/td><td>Select Order Type<\/td><td>Use limit orders to control your entry price in volatile stocks<\/td><\/tr> <tr><td>5<\/td><td>Review and Execute<\/td><td>Double-check order details before confirming purchase<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Stands Out for New Investors<\/h2> <p>For those beginning their investment journey, Pocket Option offers exceptional advantages for trading stocks like SNDX:<\/p> <ul> <li><strong>Minimum Deposit:<\/strong> Only $5 to start\u2014perfect for testing strategies<\/li> <li><strong>Rapid Verification:<\/strong> KYC completed with just one document in minutes<\/li> <li><strong>Withdrawal Options:<\/strong> Hundreds of methods including crypto, e-wallets, and traditional banking<\/li> <li><strong>User-Friendly Platform:<\/strong> Intuitive interface designed for newcomers<\/li> <\/ul> <p>The low barrier to entry makes Pocket Option ideal for investors who want to participate in biotech opportunities without committing large capital initially.<\/p> <h2>\ud83e\uddec Syndax in 2025: Oncology Innovation Leader<\/h2> <p>Syndax Pharmaceuticals isn't just another biotech company\u2014it's at the forefront of cancer treatment innovation. Their lead drug Revuforj\u00ae (revumenib) represents a first-in-class menin inhibitor that's showing remarkable results in acute leukemia patients who have exhausted other options.<\/p> <p>The company's current market position is particularly strong because they've transitioned from pure R&D to commercial execution. With $28.6 million in Q2 2025 revenue from Revuforj alone\u2014a 43% quarter-over-quarter increase\u2014they're demonstrating real commercial traction.<\/p> <p><strong>Interesting Fact from 2025:<\/strong> Syndax's research team discovered that their menin inhibitor technology might have applications beyond cancer\u2014preliminary data suggests potential in certain genetic disorders, opening up entirely new market opportunities that could be worth billions.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Current Market Position and Immediate Opportunities<\/h2>\n<p>As of August 25, 2025, Syndax Pharmaceuticals (SNDX) trades at <strong>$15.74<\/strong> per share. But here&#8217;s what makes this moment particularly exciting: mark your calendar for <strong>November 4, 2025<\/strong>\u2014the company&#8217;s next earnings release date.<\/p>\n<h3>Why November 4th Matters:<\/h3>\n<p>Based on recent history, Syndax&#8217;s earnings reports have been absolute game-changers. Their Q2 2025 report on August 4th caused a massive 15.8% single-day surge after they smashed expectations with 986% year-over-year revenue growth. The pattern is clear: when Syndax reports, the market listens\u2014and reacts dramatically.<\/p>\n<h3>Recent Earnings Impact Analysis:<\/h3>\n<ul>\n<li>August 4, 2025: +15.8% surge post-earnings (986% revenue growth beat)<\/li>\n<li>May 2025: Positive clinical data at EHA Congress sparked institutional buying<\/li>\n<li>February 2025: Steady accumulation by smart money investors<\/li>\n<\/ul>\n<p>The trend shows that positive clinical and financial news creates immediate, substantial price movements. For traders, this means positioning before these catalysts can be incredibly rewarding.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca Six-Month Price Journey: From Struggle to Breakout<\/h2>\n<p>Syndax&#8217;s stock has been on an emotional rollercoaster that perfectly illustrates biotech volatility:<\/p>\n<ul>\n<li><strong>January-March 2025:<\/strong> Consolidation around $9-11 range<\/li>\n<li><strong>April-June 2025:<\/strong> Gradual climb to $13-14 on institutional accumulation<\/li>\n<li><strong>July 2025:<\/strong> Brief pullback to $9.87 (perfect buying opportunity in hindsight)<\/li>\n<li><strong>August 2025:<\/strong> Explosive breakout to $15.74+ on stellar earnings<\/li>\n<\/ul>\n<p>The 6-month chart shows a classic &#8220;accumulation-breakout&#8221; pattern where smart money built positions before the big news hit. From the July lows around $9.87 to current levels above $15, that&#8217;s a <strong>59% gain<\/strong> in just weeks\u2014the kind of move that defines biotech investing.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<ul>\n<li><strong>2025 Year-End:<\/strong> $33-38 range (110-140% upside from current levels)<br \/> <em>Rationale: FDA decision on October 25th + continued revenue acceleration<\/em><\/li>\n<li><strong>2026 Forecast:<\/strong> $45-55 range<br \/> <em>Potential catalysts: Additional label expansions, international approvals<\/em><\/li>\n<li><strong>2028 Projection:<\/strong> $60-75 range<br \/> <em>Assuming successful commercialization and pipeline development<\/em><\/li>\n<li><strong>2030 Vision:<\/strong> $80-100+ potential<br \/> <em>Blockbuster drug status if current trajectory continues<\/em><\/li>\n<\/ul>\n<p><strong>Verdict: STRONG BUY<\/strong> &#8211; The combination of exploding revenue, FDA catalysts, and reasonable valuation creates a rare opportunity.<\/p>\n<h2>\u26a0\ufe0f Understanding the Risks: Biotech Reality Check<\/h2>\n<p>While the upside potential is enormous, Syndax carries significant risks that every investor must understand:<\/p>\n<ul>\n<li><strong>Regulatory Risk:<\/strong> The October 25th FDA decision could go either way<\/li>\n<li><strong>Clinical Trial Risk:<\/strong> Future studies might not replicate early success<\/li>\n<li><strong>Cash Burn:<\/strong> Despite growth, the company still burns substantial cash<\/li>\n<li><strong>Volatility:<\/strong> 52-week range of $8.58-$22.50 shows extreme price swings<\/li>\n<li><strong>Pipeline Concentration:<\/strong> Heavy reliance on Revuforj success<\/li>\n<\/ul>\n<p>However, the current $517.9 million cash position provides ample runway, reducing immediate dilution risk.<\/p>\n<h2>\ud83d\ude80 Positive Signals Overwhelming Risks<\/h2>\n<p>The bullish case for Syndax is compelling:<\/p>\n<ul>\n<li><strong>986% Revenue Growth:<\/strong> Not a typo\u2014actual Q2 2025 performance<\/li>\n<li><strong>FDA Priority Review:<\/strong> October 25th decision date for expanded approval<\/li>\n<li><strong>Institutional Support:<\/strong> Major funds increasing positions significantly<\/li>\n<li><strong>First-Mover Advantage:<\/strong> Only menin inhibitor with proven efficacy<\/li>\n<li><strong>Market Expansion:<\/strong> Potential addressable market increase from 5% to 30% of AML patients<\/li>\n<\/ul>\n<h2>\ud83c\udfaf What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Start Small:<\/strong> Allocate only what you can afford to lose completely\u2014biotech is high-risk<\/li>\n<li><strong>Dollar-Cost Average:<\/strong> Buy in increments rather than all at once<\/li>\n<li><strong>Set Alert for November 4th:<\/strong> Earnings could be another massive catalyst<\/li>\n<li><strong>Consider October Puts:<\/strong> Hedge against FDA decision risk<\/li>\n<\/ol>\n<p>And my favorite trader wisdom: &#8220;Buying biotech stocks is like dating\u2014sometimes you get the breakthrough treatment, sometimes you get the side effects. Always read the clinical data before committing!&#8221;<\/p>\n<h2>\u2705 How to Buy Syndax Pharmaceuticals, Inc. (SNDX) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose a Trading Platform<\/td>\n<td>Ensure it offers NASDAQ listings and biotech stocks<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete Account Funding<\/td>\n<td>Start with a comfortable amount\u2014even $100 can begin your journey<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Search &#8220;SNDX&#8221;<\/td>\n<td>Use the exact ticker symbol for accurate results<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Select Order Type<\/td>\n<td>Use limit orders to control your entry price in volatile stocks<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Review and Execute<\/td>\n<td>Double-check order details before confirming purchase<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Stands Out for New Investors<\/h2>\n<p>For those beginning their investment journey, Pocket Option offers exceptional advantages for trading stocks like SNDX:<\/p>\n<ul>\n<li><strong>Minimum Deposit:<\/strong> Only $5 to start\u2014perfect for testing strategies<\/li>\n<li><strong>Rapid Verification:<\/strong> KYC completed with just one document in minutes<\/li>\n<li><strong>Withdrawal Options:<\/strong> Hundreds of methods including crypto, e-wallets, and traditional banking<\/li>\n<li><strong>User-Friendly Platform:<\/strong> Intuitive interface designed for newcomers<\/li>\n<\/ul>\n<p>The low barrier to entry makes Pocket Option ideal for investors who want to participate in biotech opportunities without committing large capital initially.<\/p>\n<h2>\ud83e\uddec Syndax in 2025: Oncology Innovation Leader<\/h2>\n<p>Syndax Pharmaceuticals isn&#8217;t just another biotech company\u2014it&#8217;s at the forefront of cancer treatment innovation. Their lead drug Revuforj\u00ae (revumenib) represents a first-in-class menin inhibitor that&#8217;s showing remarkable results in acute leukemia patients who have exhausted other options.<\/p>\n<p>The company&#8217;s current market position is particularly strong because they&#8217;ve transitioned from pure R&#038;D to commercial execution. With $28.6 million in Q2 2025 revenue from Revuforj alone\u2014a 43% quarter-over-quarter increase\u2014they&#8217;re demonstrating real commercial traction.<\/p>\n<p><strong>Interesting Fact from 2025:<\/strong> Syndax&#8217;s research team discovered that their menin inhibitor technology might have applications beyond cancer\u2014preliminary data suggests potential in certain genetic disorders, opening up entirely new market opportunities that could be worth billions.<\/p>\n"},"faq":[{"question":"Is Syndax Pharmaceuticals profitable yet?","answer":"Not currently\u2014they report negative EPS as they invest heavily in commercialization and R&D, which is typical for growing biotech companies."},{"question":"What's the biggest risk for SNDX stock?","answer":"The October 25th FDA decision represents the most immediate risk\u2014a negative outcome could significantly impact the stock price."},{"question":"How much revenue is Syndax generating?","answer":"Q2 2025 revenue was $37.96 million, representing 986% year-over-year growth, with Revuforj contributing $28.6 million of that total."},{"question":"Should I buy before or after the FDA decision?","answer":"This depends on your risk tolerance. Buying before offers greater upside potential but higher risk, while waiting provides certainty but potentially missing gains."},{"question":"What makes Revuforj different from other cancer drugs?","answer":"It's a first-in-class menin inhibitor targeting specific genetic mutations in leukemia, offering hope for patients who haven't responded to traditional treatments."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Is Syndax Pharmaceuticals profitable yet?","answer":"Not currently\u2014they report negative EPS as they invest heavily in commercialization and R&D, which is typical for growing biotech companies."},{"question":"What's the biggest risk for SNDX stock?","answer":"The October 25th FDA decision represents the most immediate risk\u2014a negative outcome could significantly impact the stock price."},{"question":"How much revenue is Syndax generating?","answer":"Q2 2025 revenue was $37.96 million, representing 986% year-over-year growth, with Revuforj contributing $28.6 million of that total."},{"question":"Should I buy before or after the FDA decision?","answer":"This depends on your risk tolerance. Buying before offers greater upside potential but higher risk, while waiting provides certainty but potentially missing gains."},{"question":"What makes Revuforj different from other cancer drugs?","answer":"It's a first-in-class menin inhibitor targeting specific genetic mutations in leukemia, offering hope for patients who haven't responded to traditional treatments."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy Syndax Pharmaceuticals, Inc. (SNDX) shares - Investment in Syndax Pharmaceuticals, Inc. (SNDX) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy Syndax Pharmaceuticals, Inc. (SNDX) shares - Investment in Syndax Pharmaceuticals, Inc. (SNDX) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T20:35:15+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy Syndax Pharmaceuticals, Inc. (SNDX) shares &#8211; Investment in Syndax Pharmaceuticals, Inc. (SNDX) stock\",\"datePublished\":\"2025-08-25T20:35:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/\"},\"wordCount\":17,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/\",\"name\":\"How to buy Syndax Pharmaceuticals, Inc. (SNDX) shares - Investment in Syndax Pharmaceuticals, Inc. (SNDX) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"datePublished\":\"2025-08-25T20:35:15+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy Syndax Pharmaceuticals, Inc. (SNDX) shares &#8211; Investment in Syndax Pharmaceuticals, Inc. (SNDX) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy Syndax Pharmaceuticals, Inc. (SNDX) shares - Investment in Syndax Pharmaceuticals, Inc. (SNDX) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"How to buy Syndax Pharmaceuticals, Inc. (SNDX) shares - Investment in Syndax Pharmaceuticals, Inc. (SNDX) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T20:35:15+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy Syndax Pharmaceuticals, Inc. (SNDX) shares &#8211; Investment in Syndax Pharmaceuticals, Inc. (SNDX) stock","datePublished":"2025-08-25T20:35:15+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"},"wordCount":17,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/","name":"How to buy Syndax Pharmaceuticals, Inc. (SNDX) shares - Investment in Syndax Pharmaceuticals, Inc. (SNDX) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","datePublished":"2025-08-25T20:35:15+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy Syndax Pharmaceuticals, Inc. (SNDX) shares &#8211; Investment in Syndax Pharmaceuticals, Inc. (SNDX) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":351222,"slug":"how-to-buy-syndax-pharmaceuticals","post_title":"Comment acheter des actions de Syndax Pharmaceuticals, Inc. (SNDX) - Investir dans les actions de Syndax Pharmaceuticals, Inc. (SNDX)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"},"it_IT":{"locale":"it_IT","id":351227,"slug":"how-to-buy-syndax-pharmaceuticals","post_title":"Come acquistare azioni Syndax Pharmaceuticals, Inc. (SNDX) - Investire in azioni Syndax Pharmaceuticals, Inc. (SNDX)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"},"pl_PL":{"locale":"pl_PL","id":351223,"slug":"how-to-buy-syndax-pharmaceuticals","post_title":"Jak kupi\u0107 akcje Syndax Pharmaceuticals, Inc. (SNDX) - Inwestycja w akcje Syndax Pharmaceuticals, Inc. (SNDX)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"},"es_ES":{"locale":"es_ES","id":351220,"slug":"how-to-buy-syndax-pharmaceuticals","post_title":"C\u00f3mo comprar acciones de Syndax Pharmaceuticals, Inc. (SNDX) - Inversi\u00f3n en acciones de Syndax Pharmaceuticals, Inc. (SNDX)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"},"th_TH":{"locale":"th_TH","id":351226,"slug":"how-to-buy-syndax-pharmaceuticals","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 Syndax Pharmaceuticals, Inc. (SNDX) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 Syndax Pharmaceuticals, Inc. (SNDX)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"},"tr_TR":{"locale":"tr_TR","id":351224,"slug":"how-to-buy-syndax-pharmaceuticals","post_title":"Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Syndax Pharmaceuticals, Inc. (SNDX) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"},"vt_VT":{"locale":"vt_VT","id":351225,"slug":"how-to-buy-syndax-pharmaceuticals","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Syndax Pharmaceuticals, Inc. (SNDX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Syndax Pharmaceuticals, Inc. (SNDX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"},"pt_AA":{"locale":"pt_AA","id":351221,"slug":"how-to-buy-syndax-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da Syndax Pharmaceuticals, Inc. (SNDX) - Investimento em a\u00e7\u00f5es da Syndax Pharmaceuticals, Inc. (SNDX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/351205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=351205"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/351205\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334099"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=351205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=351205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=351205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}